C3-glomerulonephritis in New Zealand – a case series

[1]  C. Ciaccio,et al.  Pediatric Allergy and Immunology. , 2019, Pediatric annals.

[2]  Richard J. H. Smith,et al.  C3 glomerulopathy associated with monoclonal Ig is a distinct subtype. , 2018, Kidney international.

[3]  T. Cavero,et al.  Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. , 2015, Kidney international.

[4]  S. Barbour,et al.  Advances in the Understanding of Complement Mediated Glomerular Disease: Implications for Recurrence in the Transplant Setting , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  P. O'kelly,et al.  C3 glomerulopathy: clinicopathologic features and predictors of outcome. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[6]  V. D’Agati,et al.  Toward a working definition of C3 glomerulopathy by immunofluorescence. , 2014, Kidney international.

[7]  V. D’Agati,et al.  C3 glomerulopathy: consensus report , 2013, Kidney international.

[8]  S. Nasr,et al.  C3 glomerulonephritis associated with monoclonal gammopathy: a case series. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  N. Chen,et al.  Re-evaluation of the classification system for membranoproliferative glomerulonephritis. , 2013, Contributions to nephrology.

[10]  Richard J. H. Smith,et al.  Treatment options for C3 glomerulopathy , 2013, Current opinion in nephrology and hypertension.

[11]  N. Chen,et al.  Changing spectrum of biopsy-proven primary glomerular diseases over the past 15 years: a single-center study in China. , 2013, Contributions to nephrology.

[12]  G. Appel,et al.  Pathogenesis of the C3 glomerulopathies and reclassification of MPGN , 2012, Nature Reviews Nephrology.

[13]  J. Grünfeld,et al.  Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. , 2012, Kidney international.

[14]  Caroline Gordon,et al.  Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis , 2012, Annals of the rheumatic diseases.

[15]  V. D’Agati,et al.  Eculizumab for dense deposit disease and C3 glomerulonephritis. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[16]  S. Nasr,et al.  Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[17]  W. Wong,et al.  Outcome of severe acute post-streptococcal glomerulonephritis in New Zealand children , 2009, Pediatric Nephrology.

[18]  John D Lambris,et al.  New approaches to the treatment of dense deposit disease. , 2007, Journal of the American Society of Nephrology : JASN.

[19]  A. Denman,et al.  Annals of the Rheumatic Diseases , 1980 .

[20]  G. Russ,et al.  Burden of end-stage renal disease among indigenous peoples in Australia and New Zealand. , 2003, Kidney international. Supplement.

[21]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[22]  N. Gretz,et al.  Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: A long‐term follow‐up , 2001, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[23]  N. Gretz,et al.  Outcome of idiopathic membranoproliferative glomerulonephritis in children , 1996 .

[24]  C. Swainson,et al.  Mesangiocapillary glomerulonephritis: A long‐term study of 40 cases , 1983, The Journal of pathology.